These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 21746763)

  • 61. Structural characterization of human heparanase reveals insights into substrate recognition.
    Wu L; Viola CM; Brzozowski AM; Davies GJ
    Nat Struct Mol Biol; 2015 Dec; 22(12):1016-22. PubMed ID: 26575439
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bacterial expression and functional reconstitution of human heparanase.
    Winkler S; Schweiger D; Wei Z; Rajkovic E; Kungl AJ
    Carbohydr Res; 2014 May; 389():72-7. PubMed ID: 24656445
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species.
    Bar-Ner M; Eldor A; Wasserman L; Matzner Y; Cohen IR; Fuks Z; Vlodavsky I
    Blood; 1987 Aug; 70(2):551-7. PubMed ID: 2955820
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Langerin-heparin interaction: two binding sites for small and large ligands as revealed by a combination of NMR spectroscopy and cross-linking mapping experiments.
    Muñoz-García JC; Chabrol E; Vivès RR; Thomas A; de Paz JL; Rojo J; Imberty A; Fieschi F; Nieto PM; Angulo J
    J Am Chem Soc; 2015 Apr; 137(12):4100-10. PubMed ID: 25747117
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Heparanase-mediated cleavage of macromolecular heparin accelerates release of granular components of mast cells from extracellular matrices.
    Higashi N; Waki M; Sue M; Kogane Y; Shida H; Tsunekawa N; Hasan A; Sato T; Kitahara A; Kasaoka T; Hayakawa Y; Nakajima M; Irimura T
    Biochem J; 2014 Mar; 458(2):291-9. PubMed ID: 24344642
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Keratinocytes-associated chemokines and enzymatically quiescent heparanase induce the binding of resting CD4+ T cells.
    Hershkoviz R; Marikovsky M; Gilat D; Lider O
    J Invest Dermatol; 1996 Feb; 106(2):243-8. PubMed ID: 8601723
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase.
    Schoenfeld AK; Vierfuß S; Lühn S; Alban S
    J Pharm Biomed Anal; 2014 Jul; 95():130-8. PubMed ID: 24667567
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Enzymatic degradation of heparin-modified hydrogels and its effect on bioactivity.
    Nilasaroya A; Martens PJ; Whitelock JM
    Biomaterials; 2012 Aug; 33(22):5534-40. PubMed ID: 22575836
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase.
    Abboud-Jarrous G; Rangini-Guetta Z; Aingorn H; Atzmon R; Elgavish S; Peretz T; Vlodavsky I
    J Biol Chem; 2005 Apr; 280(14):13568-75. PubMed ID: 15659389
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Computational docking, molecular dynamics simulation and subsite structure analysis of a maltogenic amylase from Bacillus lehensis G1 provide insights into substrate and product specificity.
    Manas NH; Bakar FD; Illias RM
    J Mol Graph Model; 2016 Jun; 67():1-13. PubMed ID: 27155296
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Design of an Ultralow Molecular Weight Heparin That Resists Heparanase Biodegradation.
    Ham H; Xu Y; Haller CA; Dai E; Stancanelli E; Liu J; Chaikof EL
    J Med Chem; 2023 Feb; 66(3):2194-2203. PubMed ID: 36706244
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Heparanases produce distinct populations of heparan sulfate glycosaminoglycans in Chinese hamster ovary cells.
    Bame KJ; Robson K
    J Biol Chem; 1997 Jan; 272(4):2245-51. PubMed ID: 8999930
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Homology modeling and docking mechanism of the mercaptosuccinate and methotrexate to P. falciparum 1-Cys peroxiredoxin: a preliminary molecular study.
    Hamza A
    J Biomol Struct Dyn; 2002 Aug; 20(1):7-20. PubMed ID: 12144348
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Conformation and dynamics of heparin and heparan sulfate.
    Mulloy B; Forster MJ
    Glycobiology; 2000 Nov; 10(11):1147-56. PubMed ID: 11087707
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Heparanase Activates Antithrombin through the Binding to Its Heparin Binding Site.
    Bohdan N; Espín S; Águila S; Teruel-Montoya R; Vicente V; Corral J; Martínez-Martínez I
    PLoS One; 2016; 11(6):e0157834. PubMed ID: 27322195
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Heparanase as an Additional Tool for Detecting Structural Peculiarities of Heparin Oligosaccharides.
    Alekseeva A; Urso E; Mazzini G; Naggi A
    Molecules; 2019 Dec; 24(23):. PubMed ID: 31810297
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mechanisms of heparanase inhibitors in cancer therapy.
    Heyman B; Yang Y
    Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Binding of interferon-gamma to heparan sulfate is restricted to the heparin-like domains and involves carboxylic--but not N-sulfated--groups.
    Lortat-Jacob H; Grimaud JA
    Biochim Biophys Acta; 1992 Sep; 1117(2):126-30. PubMed ID: 1525174
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cloning, expression, and characterization of an alternatively spliced variant of human heparanase.
    Nasser NJ; Avivi A; Shushy M; Vlodavsky I; Nevo E
    Biochem Biophys Res Commun; 2007 Mar; 354(1):33-8. PubMed ID: 17208203
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Polymeric fluorescent heparin as one-step FRET substrate of human heparanase.
    Sistla JC; Morla S; Alabbas AB; Kalathur RC; Sharon C; Patel BB; Desai UR
    Carbohydr Polym; 2019 Feb; 205():385-391. PubMed ID: 30446119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.